Work

Genomarker AI drug-reversal benchmark: protocol v1

Year: 2026
Type: article
Abstract: The frozen protocol of the Genomarker AI drug-reversal benchmark, deposited before any benchmark run. The benchmark asks how well a connectivity-style reversal ranking of LINCS L1000 compounds against each cancer's disease signature recovers the drugs approved for that cancer, compared with a leave-one-cancer-out frequent-hitter baseline and a proliferation-query baseline. protocol.yaml fixes the positives (approvals in the query cancer), the excluded trial stages, the minimum number of profiled positives, the recall fractions, the stratified bootstrap (2,000 draws, seed 20261111, 95% level), the validation rule and the normal-reference decision rule; its comment block states the tie and leave-out rules in plain words. sha256 of protocol.yaml: cad2b63a91784356df4f7272911a07be62cdfa5fe1830a610ff23e34a02953f2. Every benchmark run records this sha256 and this DOI. Nothing is tuned after a run; a method change is a new protocol version, published beside v1.
Language: English
Subfield: Drug Discovery
Open Access status: green
OpenAlex ID: W7233568128
FWCI:
Cites:
Cited by:
Related to: